All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2021-06-10T14:54:16.000Z

What advances have there been in biomarkers for AML?

By Marcia Rato, Joshua Reid, Camilla Rossi
Jun 10, 2021
Share:

Bookmark this article

During the 2021 ASCO Annual Meeting, the AML Hub spoke with Chris Hourigan, National Institutes of Health, Bethesda, US. We asked, What advances have there been in biomarkers for AML?

What advances have there been in biomarkers for AML?

Hourigan summarises three abstracts from ASCO, including MRD testing for risk stratification, using a 'mechanistic hubris' that moves past using single mutations, and finally, understanding the host microenvironment instead of solely focusing on leukemia biology.

 

More about...
ASCO 2021

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
42 votes - 3 days left ...

Related articles

Add bookmark

How can venetoclax combinations be used in preparation for transplant?

During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked, How can venetoclax...

Dec 18, 2021
Add bookmark

How can venetoclax combinations be used in preparation for transplant?

During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Curtis Lachowiez, MD Anderson Cancer...

Dec 18, 2021
Add bookmark

How efficacious is CAR-T in childhood AML?

During the 2021 ASCO Annual Meeting, the AML Hub spoke with Hui Zhang, Guangzhou Women and Children's Medical Center, Guangzhou, CN. We asked, How efficacious is CAR-T in childhood AML?

Jun 30, 2021
Add bookmark

How efficacious is CAR-T in childhood AML?

During the 2021 ASCO Annual Meeting, the AML Hub spoke with Hui Zhang, Guangzhou Women and Children's Medical Center, Guangzhou, CN. We asked, How...

Jun 30, 2021

Newsletter

Subscribe to get the best content related to AML delivered to your inbox